Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials

In recent years, the use of interleukin (IL) 23 inhibitors in the treatment of psoriatic arthritis (PsA) has been the subject of much research. By specifically binding to the p19 subunit of IL-23, IL-23 inhibitors block downstream signaling pathways and inhibit inflammatory responses. The objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xiaojing, Shentu, Haojie, He, Yujing, Lai, Haijia, Xu, Chen, Chen, Meiling, Zhu, Haowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Interpretive Synthesis Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425519/
https://www.ncbi.nlm.nih.gov/pubmed/36811818
http://dx.doi.org/10.1007/s12026-023-09366-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425519/
https://www.ncbi.nlm.nih.gov/pubmed/36811818
http://dx.doi.org/10.1007/s12026-023-09366-4

Ejemplares similares